Azilsartan Kamedoxomil
A prodrug that is hydrolyzed after absorption to azilsartan, an angiotensin II receptor blocker that lowers blood pressure by preventing angiotensin II from constricting blood vessels.
Moleküler Ağırlık
606,6000 g/mol
TPSA
129,00 Ų
Terapötik Alanlar
Etki Mekanizması
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[n-]2)cc1.[K+]
InChI
InChI=1S/C30H24N4O8.K/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26;/h4-14H,3,15-16H2,1-2H3,(H,32,33,36);/q;+1/p-1
Molecular Formula
C30H23KN4O8
HBD / HBA
- / 11
Döndürülebilir Bağlar
10
Ağır Atomlar
43
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A prodrug that is hydrolyzed after absorption to azilsartan, an angiotensin II receptor blocker that lowers blood pressure by preventing angiotensin II from constricting blood vessels.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Azilsartan Kamedoxomil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103795. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23699544. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="azilsartan-kamedoxomil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/azilsartan-kamedoxomil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/azilsartan-kamedoxomil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/azilsartan-kamedoxomil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="azilsartan-kamedoxomil"></drugfyi-drug>